OR WAIT null SECS
© 2023 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 10, 2021.
Most patients share a fear of falling or psychological distress that can exacerbate physical limitations. In fact, more than half of RA patients report significant fear of falling.
Click the image to view the story.
Philip Conaghan, MBBS, PhD, discusses his presentation entitled, “Meaningful Improvements in WOMAC Pain and Physical Function in 3 Phase 3 Trials of Tanezumab in Patients With Moderate-to-Severe Osteoarthritis: A Responder Analysis.”
Click the image to view the story.
Disease activity, safety, and the occurrence of adverse events were similar in patients with juvenile idiopathic arthritis receiving either etanercept or the biosimilars Benepali and Erelzi.
Click the image to view the story.
The survey found that 22.3% (n = 62) patients reduced or interrupted treatment and only 3.9% (n = 11) patients stopped treatment entirely. The duration of disease (p = 0.023) and disease activity (p = 0.001) were significant contributing factors in the decision to discontinue treatment.
Click the image to view the story.